Goserelin
Estrogen-Receptor Positive Breast Cancer
Explore 74 assets in Estrogen-Receptor Positive Breast Cancer →Floatz Rating
BB66/100
Confidence
Indicative
Sponsor
Memorial Sloan Kettering Cancer Center
Modality
protein_peptide
Development Phase
Phase 3
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
59High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT07483307CT.gov A Study of the Impact of Endocrine Therapy on Surgical Outcomes in People With Lobular Breast Cancer | — | Recruiting | — | — | — |
NCT07085767CT.gov Palazestrant in Combination With Ribociclib for the First-line Treatment of ER+/HER2- Advanced Breast Cancer | — | Recruiting | — | — | — |
NCT06065748CT.gov A Study to Evaluate Efficacy and Safety of Giredestrant Compared With Fulvestrant (Plus a CDK4/6 Inhibitor), in Participants With ER-Positive, HER2-Negative Advanced Breast Cancer Resistant to Adjuvant Endocrine Therapy (pionERA Breast Cancer) | — | Recruiting | — | — | — |
NCT06188520CT.gov A First-in-human Dose Escalation and Expansion Study to Evaluate the Safety, and Tolerability of AZD8421 Alone or in Combination in Participants With Selected Advanced or Metastatic Solid Tumors | — | Recruiting | — | — | — |
NCT05607004CT.gov (Z)-Endoxifen for the Treatment of Premenopausal Women With ER+/HER2- Breast Cancer | — | Recruiting | — | — | — |
NCT05720260CT.gov Immunotherapy, Hormone Therapy, and AKT Inhibitor for Premenopausal ER Positive MBC | — | Recruiting | — | — | — |
NCT05163106CT.gov Neoadjuvant Treatment of Locally-advanced Breast Cancer Patients With Ribociclib and Letrozole | — | Completed | — | — | — |
NCT05508906CT.gov Phase 1b Study of OP-1250 (Palazestrant) in Combination With Ribociclib, Alpelisib, Everolimus, or Atirmociclib in ER+, HER2- Breast Cancer | — | Recruiting | — | — | — |
NCT04802759CT.gov A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Participants With Breast Cancer | — | Recruiting | — | — | — |
NCT04551495CT.gov Neoadjuvant Study of Targeting ROS1 in Combination With Endocrine Therapy in Invasive Lobular Carcinoma of the Breast (ROSALINE) | — | Unknown | — | — | — |
Show 4 more trialsShow fewer
NCT02657928CT.gov Ribociclib and Letrozole in Treating Patients With Relapsed ER Positive Ovarian, Fallopian Tube, Primary Peritoneal, or Endometrial Cancer | — | Completed | — | — | — |
NCT01776008CT.gov Akt Inhibitor MK-2206 and Anastrozole With or Without Goserelin Acetate in Treating Patients With Stage II-III Breast Cancer | — | Terminated | — | — | — |
NCT01368263CT.gov Goserelin and Letrozole or Anastrozole in Premenopausal Patients With Stage II-III Estrogen Receptor-Positive Breast Cancer | — | Terminated | — | — | — |
NCT01149356CT.gov RO4929097 And Exemestane in Treating Pre- and Postmenopausal Patients With Advanced or Metastatic Breast Cancer | — | Terminated | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
89High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Estrogen-Receptor Positive Breast Cancer
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Goserelin (this asset) | Memorial Sloan Kettering Cancer Center | P3 | BB · 66 |
| Exemestane | National Cancer Institute (NCI) | P4 | BBB |
| Everolimus | UNC Lineberger Comprehensive Cancer Center | P4 | BBB |
| Tamoxifen | Dana-Farber Cancer Institute | P4 | BB |
| Palbociclib | Forward Pharmaceuticals Co., Ltd. | P3 | BB |
| Giredestrant | Hoffmann-La Roche | P3 | BB |
| Capivasertib | Imperial College London | P2 | BB |
| Abemaciclib | Jonsson Comprehensive Cancer Center | P3 | BB |
| Ribociclib | National Cancer Institute (NCI) | P3 | BB |
+42 more in the Estrogen-Receptor Positive Breast Cancer cohort
Other indications for Goserelin
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Breast Cancer | — | P4 | BB · 70 |
| Prostate Carcinoma | — | P3 | BB · 69 |
| Prostate Adenocarcinoma | — | P3 | BB · 69 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Goserelin in Estrogen-Receptor Positive Breast Cancer. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 9, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/goserelin-estrogen-receptor-positive-breast-cancer-68313
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →